HRP20130245T1 - Kvetiapinski pripravak - Google Patents
Kvetiapinski pripravak Download PDFInfo
- Publication number
- HRP20130245T1 HRP20130245T1 HRP20130245AT HRP20130245T HRP20130245T1 HR P20130245 T1 HRP20130245 T1 HR P20130245T1 HR P20130245A T HRP20130245A T HR P20130245AT HR P20130245 T HRP20130245 T HR P20130245T HR P20130245 T1 HRP20130245 T1 HR P20130245T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical preparation
- weight
- preparation according
- quetiapine
- acid
- Prior art date
Links
- 229960004431 quetiapine Drugs 0.000 title claims 10
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 title claims 6
- 239000000203 mixture Substances 0.000 title claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 4
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- ZTHJULTYCAQOIJ-WXXKFALUSA-N quetiapine fumarate Chemical compound [H+].[H+].[O-]C(=O)\C=C\C([O-])=O.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 ZTHJULTYCAQOIJ-WXXKFALUSA-N 0.000 claims 4
- 229920006318 anionic polymer Polymers 0.000 claims 3
- 239000000679 carrageenan Substances 0.000 claims 3
- 229920001525 carrageenan Polymers 0.000 claims 3
- 229940113118 carrageenan Drugs 0.000 claims 3
- 150000007524 organic acids Chemical class 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 2
- 235000015165 citric acid Nutrition 0.000 claims 2
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 claims 2
- 239000001530 fumaric acid Substances 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 2
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 1
- 239000005711 Benzoic acid Substances 0.000 claims 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- 235000010418 carrageenan Nutrition 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000013265 extended release Methods 0.000 claims 1
- 235000011087 fumaric acid Nutrition 0.000 claims 1
- 229940093915 gynecological organic acid Drugs 0.000 claims 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 1
- 229960001375 lactose Drugs 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 239000001630 malic acid Substances 0.000 claims 1
- 235000011090 malic acid Nutrition 0.000 claims 1
- 235000005985 organic acids Nutrition 0.000 claims 1
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 claims 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000001384 succinic acid Substances 0.000 claims 1
- 235000011044 succinic acid Nutrition 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Claims (13)
1. Farmaceutski pripravak s produljenim otpuštanjem, koji sadrži kvetiapin, ili njegovu sol, i λ-karagenan, naznačen time što navedeni pripravak dolazi u obliku tablete.
2. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što je kvetiapin u obliku kvetiapin-hemifumarata.
3. Farmaceutski pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što dodatno sadrži organsku kiselinu.
4. Farmaceutski pripravak u skladu s patentnim zahtjevom 3, naznačen time što se organsku kiselinu bira iz skupine koju čine limunska kiselina, fumarna kiselina, vinska kiselina, benzojeva kiselina, jabučna kiselina, askorbinska kiselina, jantarna kiselina i njihove smjese.
5. Farmaceutski pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što dodatno sadrži anionski polimer.
6. Farmaceutski pripravak u skladu s patentnim zahtjevom 5, naznačen time što se anionski polimer bira iz skupine koju čine celulozni acetat-ftalat, kopolimer metakrilne kiseline, celulozni acetat-sukcinat, polivinil-acetat-ftalat, hidroksipropilmetilcelulozni ftalat i/ili njihove smjese.
7. Farmaceutski pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što dodatno sadrži polietilen-glikol.
8. Farmaceutski pripravak u skladu s patentnim zahtjevom 7, naznačen time što je molekulska težina polietilen-glikola u rasponu od 4.000 do 8.000.
9. Farmaceutski pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što dodatno sadrži manitol.
10. Farmaceutski pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što sadrži:
25 do 55 %, težinski, po mogućnosti 30 do 45 %, težinski, kvetiapina, po mogućnosti u obliku kvetiapin-hemifumarata,
15 do 65 %, težinski, po mogućnosti 20 do 55 %, težinski, neželirajućeg karagenana, po mogućnosti λ-karagenana,
te izborno 1 do 2 %, težinski, maziva, po mogućnosti magnezijevog stearata,
na osnovu ukupne težine pripravka.
11. Farmaceutski pripravak u skladu s patentnim zahtjevom 10, naznačen time što dodatno sadrži:
10 do 40 %, težinski, razrjeđivača, po mogućnosti laktoze, a osobito α-laktoza monohidrata, manitola i/ili dikalcijevog fosfata dihidrata i/ili
5 do 15 %, težinski, organske kiseline, po mogućnosti limunske kiseline i/ili fumarne kiseline i/ili
10 do 35 %, težinski, anionskog polimera, a osobito HPMC-acetat-sukcinata i/ili kopolimera metakrilne kiseline i/ili
12 do 24 %, težinski, polietilen-glikola, a osobito polietilen-glikola, prosječne molekulske težine od 4.000,
na osnovu ukupne težine pripravka.
12. Farmaceutski pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je kvetiapin u obliku kvetiapin-hemifumarata, u kristalnom obliku I iz dokumenta WO 03/080065.
13. Farmaceutski pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što sadrži 50 do 800 mg kvetiapina u obliku kvetiapin-hemifumarata.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SI200800193A SI22850A (sl) | 2008-08-01 | 2008-08-01 | Pripravek kvetiapina |
| SI200900073 | 2009-03-18 | ||
| PCT/EP2009/005573 WO2010012490A1 (en) | 2008-08-01 | 2009-07-31 | Quetiapine composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20130245T1 true HRP20130245T1 (hr) | 2013-04-30 |
Family
ID=41112567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130245AT HRP20130245T1 (hr) | 2008-08-01 | 2013-03-21 | Kvetiapinski pripravak |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2262486B1 (hr) |
| DE (1) | DE202009018024U1 (hr) |
| DK (1) | DK2262486T3 (hr) |
| EA (1) | EA018638B1 (hr) |
| ES (1) | ES2402342T3 (hr) |
| HR (1) | HRP20130245T1 (hr) |
| PL (1) | PL2262486T3 (hr) |
| PT (1) | PT2262486E (hr) |
| SI (1) | SI2262486T1 (hr) |
| WO (1) | WO2010012490A1 (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2309994A2 (en) * | 2008-07-01 | 2011-04-20 | Lupin Limited | Sustained release pharmaceutical compositions comprising quetiapine |
| EP2373319B1 (en) * | 2009-01-05 | 2013-07-31 | Torrent Pharmaceuticals Limited | Sustained release pharmaceutical composition of quetiapine and process for preparation thereof |
| EP2233130A1 (en) * | 2009-03-23 | 2010-09-29 | Genepharm (Europe) Trading Limited | A sustained release oral composition of an antipsychotic agent |
| WO2011154118A1 (en) | 2010-06-07 | 2011-12-15 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Quetiapine prolonged-release tablets |
| TR201008261A1 (tr) | 2010-10-08 | 2012-04-24 | Sanovel İlaç San. Ve Ti̇c. A.Ş. | Kontrollü salım gerçekleştiren ketiapin formülasyonları |
| DE102011115690A1 (de) | 2011-10-11 | 2013-04-11 | Acino Pharma Ag | Quetiapin enthaltende Formulierungen |
| WO2013169977A2 (en) * | 2012-05-10 | 2013-11-14 | Fmc Corporation | Controlled release solid dose form |
| RS62844B1 (sr) | 2015-06-18 | 2022-02-28 | Estetra Srl | Orodisperzibilna dozna jedinica koja sadrži komponentu estetrola |
| JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607684D0 (en) | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| GB8705574D0 (en) | 1987-03-10 | 1987-04-15 | Ici Plc | Preparation of thiazepine compound |
| GB9611328D0 (en) | 1996-05-31 | 1996-08-07 | Zeneca Ltd | Pharmaceutical compositions |
| GB9716161D0 (en) | 1997-08-01 | 1997-10-08 | Zeneca Ltd | Process |
| IT1297461B1 (it) | 1997-10-29 | 1999-12-17 | Ciocca Maurizio | Preparazione di compresse a rilascio controllato a base di complessi tra carragenano e farmaci basici solubili |
| GB9922271D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Formulation |
| HU227039B1 (en) | 2000-01-25 | 2010-05-28 | Egis Gyogyszergyar Nyilvanosan | New process for the production of quetiapine and intermediates therefor |
| US6287599B1 (en) | 2000-12-20 | 2001-09-11 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
| AR034517A1 (es) | 2001-06-21 | 2004-02-25 | Astrazeneca Ab | Formulacion farmaceutica |
| JP3624954B1 (ja) | 2001-11-07 | 2005-03-02 | 藤沢薬品工業株式会社 | 分散不良薬物の溶出性を改善する方法 |
| CA2479668A1 (en) | 2002-03-20 | 2003-10-02 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of quetiapine hemifumarate |
| WO2005028457A1 (en) | 2003-09-23 | 2005-03-31 | Fermion Oy | Preparation of quetiapine |
| CA2542836A1 (en) | 2003-10-21 | 2005-05-12 | Alpharma, Inc. | Pharmaceutical formulations containing quetiapine |
| RU2008104638A (ru) | 2005-07-07 | 2009-08-20 | Фарнэм Компаниз, Инк. (Us) | Фармацевтические композиции хорошо растворимых в воде лекарственных средств, обеспечивающих их замедленное высвобождение |
| WO2007036599A1 (en) | 2005-09-30 | 2007-04-05 | Fermion Oy | New crystallization process of quetiapine hemifumarate |
| EP2131817A2 (en) | 2007-03-09 | 2009-12-16 | Synthon B.V. | Pharmaceutical composition of quetiapine fumarate |
| EA020477B1 (ru) | 2008-11-26 | 2014-11-28 | Крка, Товарна Здравил, Д. Д., Ново Место | Композиция кветиапина |
-
2009
- 2009-07-31 EP EP09777586A patent/EP2262486B1/en active Active
- 2009-07-31 SI SI200930534T patent/SI2262486T1/sl unknown
- 2009-07-31 DE DE202009018024U patent/DE202009018024U1/de not_active Expired - Lifetime
- 2009-07-31 EA EA201100286A patent/EA018638B1/ru not_active IP Right Cessation
- 2009-07-31 ES ES09777586T patent/ES2402342T3/es active Active
- 2009-07-31 PL PL09777586T patent/PL2262486T3/pl unknown
- 2009-07-31 WO PCT/EP2009/005573 patent/WO2010012490A1/en active Application Filing
- 2009-07-31 DK DK09777586.0T patent/DK2262486T3/da active
- 2009-07-31 PT PT97775860T patent/PT2262486E/pt unknown
-
2013
- 2013-03-21 HR HRP20130245AT patent/HRP20130245T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010012490A1 (en) | 2010-02-04 |
| EA201100286A1 (ru) | 2011-08-30 |
| ES2402342T3 (es) | 2013-04-30 |
| EP2262486A1 (en) | 2010-12-22 |
| EA018638B1 (ru) | 2013-09-30 |
| PT2262486E (pt) | 2013-03-27 |
| DE202009018024U1 (de) | 2010-12-09 |
| EP2262486B1 (en) | 2013-01-02 |
| SI2262486T1 (sl) | 2013-04-30 |
| DK2262486T3 (da) | 2013-03-25 |
| PL2262486T3 (pl) | 2013-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20130245T1 (hr) | Kvetiapinski pripravak | |
| HRP20170030T1 (hr) | Sredstvo za terapiju upalne bolesti crijeva | |
| AR082861A1 (es) | Forma de dosificacion resistente a alteracion que comprende un polimero anionico | |
| HRP20180387T1 (hr) | Oralne formulacije deferasiroksa | |
| HRP20211752T1 (hr) | Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena | |
| HRP20171718T1 (hr) | Termooblikovan, farmaceutski oblik doziranja otporan na mijenjanje koji sadrži cink | |
| WO2008088030A1 (ja) | 血栓もしくは塞栓に関連する疾患の予防又は治療用組成物 | |
| JP2012255007A5 (hr) | ||
| HRP20170505T1 (hr) | Polimerne soli alifatskog amina za tabletiranje | |
| AR082862A1 (es) | Forma de dosificacion resistente a alteracion que comprende un polimero anionico | |
| RU2013114407A (ru) | Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль | |
| EA201390600A1 (ru) | Терапевтические наночастицы с сополимерами с большим молекулярным весом | |
| WO2007068615A3 (en) | Hcv prodrug formulation | |
| FI3586825T3 (fi) | Biohajoavat lääkeaineen annostelukoostumukset | |
| NZ594648A (en) | Sustained release oral dosage forms of an r-baclofen prodrug | |
| NO20080202L (no) | Nanopartikulaere clopidogrel og aspirin kombinasjonsformuleringer | |
| RS52813B (en) | PHARMACEUTICAL DOSAGE FORMS | |
| AR077420A1 (es) | Forma de dosificacion resistente a la manipulacion para opiaceos sensibles a la oxidacion | |
| JP2014521659A5 (hr) | ||
| NZ604055A (en) | Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate | |
| WO2011053003A3 (en) | Gastric-retentive sustained release formulation containing pregabalin, polyethyleneoxide and pva-peg graft copolymer | |
| TR200904159A1 (tr) | Değiştirilmiş salım sağlayan emoksipin formülasyonları. | |
| NZ611148A (en) | Formulations comprising polyethylene glycol | |
| AR057212A1 (es) | Composicion de liberacion prolongada del principio activo, su proceso de preparacion y su utilizacion | |
| HRP20201696T1 (hr) | Farmaceutska parenteralna formulacija koja sadrži kargluminsku kiselinu |